FDA approves first new drug developed for women with postpartum depression
The FDA approved Sage Therapeutics' brexanolone, the first drug specifically targeted to treat postpartum depression.
by Adam Feuerstein
Mar 19, 2019
3 minutes
The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.
Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.
“This approval is important for postpartum depression patients and it’s important
You’re reading a preview, subscribe to read more.
Start your free 30 days